Jeong Hoo Lee1, Jenny E Lee1, Veronica Harsh1, Anita H Clayton2. 1. Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, USA. 2. Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, USA. ahc8v@virginia.edu.
Abstract
PURPOSE OF REVIEW: This review article discusses the controversy in the DSM-5 conceptualization and diagnostic criteria for female sexual dysfunction (FSD). An overview of recent studies on available treatments for hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), and genitopelvic pain/penetration disorder (GPPD) is provided. RECENT FINDINGS: Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremelanotide for HSDD; removal of flibanserin alcohol REMS; and development of new technology to enhance bioavailability and brain delivery of treatments. The DSM-5 revision combining HSDD and FSAD into one diagnostic category is a less accurate characterization of these separate disorders and may hinder access to demonstrated effective treatments for the women with these conditions. There are a wide range of pharmacological, other physiological, and psychological treatment options available for women with FSD, which can be offered based on their specific symptoms, potential benefits/risks, and preferences.
PURPOSE OF REVIEW: This review article discusses the controversy in the DSM-5 conceptualization and diagnostic criteria for female sexual dysfunction (FSD). An overview of recent studies on available treatments for hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), and genitopelvic pain/penetration disorder (GPPD) is provided. RECENT FINDINGS: Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremelanotide for HSDD; removal of flibanserin alcohol REMS; and development of new technology to enhance bioavailability and brain delivery of treatments. The DSM-5 revision combining HSDD and FSAD into one diagnostic category is a less accurate characterization of these separate disorders and may hinder access to demonstrated effective treatments for the women with these conditions. There are a wide range of pharmacological, other physiological, and psychological treatment options available for women with FSD, which can be offered based on their specific symptoms, potential benefits/risks, and preferences.
Authors: Jan L Shifren; Brigitta U Monz; Patricia A Russo; Anthony Segreti; Catherine B Johannes Journal: Obstet Gynecol Date: 2008-11 Impact factor: 7.661
Authors: Catherine B Johannes; Anita H Clayton; Dawn M Odom; Raymond C Rosen; Patricia A Russo; Jan L Shifren; Brigitta U Monz Journal: J Clin Psychiatry Date: 2009-12 Impact factor: 4.384
Authors: Stanley E Althof; Sandra R Leiblum; Marie Chevret-Measson; Uwe Hartmann; Stephen B Levine; Marita McCabe; Michael Plaut; Oswaldo Rodrigues; Kevan Wylie Journal: J Sex Med Date: 2005-11 Impact factor: 3.802
Authors: Irwin Goldstein; Noel N Kim; Anita H Clayton; Leonard R DeRogatis; Annamaria Giraldi; Sharon J Parish; James Pfaus; James A Simon; Sheryl A Kingsberg; Cindy Meston; Stephen M Stahl; Kim Wallen; Roisin Worsley Journal: Mayo Clin Proc Date: 2016-12-01 Impact factor: 7.616